See more : PFA Invest Danske Aktier (PFIDKA.CO) Income Statement Analysis – Financial Results
Complete financial analysis of BrainsWay Ltd. (BWAY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BrainsWay Ltd., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Vow ASA (SSHPF) Income Statement Analysis – Financial Results
- International Tower Hill Mines Ltd. (1I1.F) Income Statement Analysis – Financial Results
- Ascentech K.K. (3565.T) Income Statement Analysis – Financial Results
- Beacon Redevelopment Industrial Corporation (BCND) Income Statement Analysis – Financial Results
- Organization of Football Prognostics S.A. (GRKZF) Income Statement Analysis – Financial Results
BrainsWay Ltd. (BWAY)
About BrainsWay Ltd.
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.79M | 27.18M | 29.66M | 22.06M | 23.10M | 16.40M | 11.15M | 11.52M | 6.80M | 3.38M | 1.19M | 364.25K |
| Cost of Revenue | 8.31M | 7.13M | 6.60M | 5.06M | 5.13M | 3.59M | 2.60M | 2.43M | 1.47M | 656.00K | 199.00K | 46.07K |
| Gross Profit | 23.48M | 20.05M | 23.06M | 17.00M | 17.97M | 12.81M | 8.55M | 9.10M | 5.33M | 2.72M | 990.00K | 318.18K |
| Gross Profit Ratio | 73.86% | 73.77% | 77.75% | 77.07% | 77.80% | 78.11% | 76.72% | 78.94% | 78.44% | 80.59% | 83.26% | 87.35% |
| Research & Development | 6.67M | 7.68M | 6.39M | 5.82M | 7.88M | 6.16M | 5.34M | 3.79M | 4.10M | 6.44M | 3.69M | 5.97M |
| General & Administrative | 5.32M | 6.85M | 5.78M | 4.72M | 4.39M | 8.23M | 7.47M | 5.74M | 3.61M | 2.34M | 1.43M | 1.31M |
| Selling & Marketing | 16.46M | 18.20M | 15.88M | 11.28M | 13.27M | 3.11M | 1.83M | 1.21M | 1.93M | 1.21M | 633.00K | 140.34K |
| SG&A | 21.64M | 25.05M | 21.66M | 16.01M | 17.66M | 11.34M | 9.30M | 6.95M | 5.54M | 3.55M | 2.06M | 1.45M |
| Other Expenses | 133.00K | 0.00 | 0.00 | 0.00 | 916.00K | 427.00K | 523.00K | 426.00K | 200.00K | 11.00K | -504.00K | 0.00 |
| Operating Expenses | 28.44M | 32.73M | 28.06M | 21.83M | 26.45M | 17.92M | 15.16M | 11.17M | 9.84M | 10.00M | 5.26M | 5.95M |
| Cost & Expenses | 36.74M | 39.86M | 34.66M | 26.89M | 31.58M | 21.51M | 17.76M | 13.59M | 11.31M | 10.66M | 5.46M | 5.99M |
| Interest Income | 2.17M | 1.11M | 225.00K | 61.00K | 175.00K | 44.00K | 22.00K | 12.00K | 18.00K | 93.00K | 304.00K | 288.19K |
| Interest Expense | 48.00K | 46.00K | 1.42M | 319.00K | 398.00K | 354.00K | 360.00K | 404.00K | 98.00K | 525.00K | 283.00K | 0.00 |
| Depreciation & Amortization | 1.34M | 1.53M | 1.69M | 1.62M | 2.80M | 1.23M | 1.07M | 649.00K | 611.00K | 336.00K | 206.00K | 109.28K |
| EBITDA | -2.56M | -11.45M | -4.67M | -3.46M | -6.58M | -4.40M | -5.56M | -1.34M | -3.38M | -5.68M | -4.06M | -5.57M |
| EBITDA Ratio | -8.06% | -41.02% | -11.17% | -21.89% | -28.50% | -26.85% | -49.92% | -12.75% | -57.54% | -203.22% | -79.98% | -1,530.22% |
| Operating Income | -4.96M | -12.68M | -5.00M | -4.83M | -8.48M | -5.11M | -6.61M | -2.07M | -4.51M | -7.28M | -4.27M | -5.68M |
| Operating Income Ratio | -15.60% | -46.67% | -16.86% | -21.89% | -36.69% | -31.19% | -59.32% | -17.95% | -66.25% | -215.30% | -358.87% | -1,560.22% |
| Total Other Income/Expenses | 1.01M | -351.00K | -1.42M | -319.00K | -1.43M | -1.16M | -274.00K | -328.00K | 418.00K | 732.00K | -2.83M | -233.28K |
| Income Before Tax | -3.95M | -13.03M | -6.42M | -5.15M | -9.91M | -6.27M | -6.89M | -2.40M | -4.09M | -6.55M | -7.09M | -5.92M |
| Income Before Tax Ratio | -12.41% | -47.96% | -21.64% | -23.34% | -42.88% | -38.24% | -61.78% | -20.80% | -60.10% | -193.64% | -596.64% | -1,624.27% |
| Income Tax Expense | 251.00K | 315.00K | 43.00K | 237.00K | 422.00K | 209.00K | 169.00K | 404.00K | 98.00K | 525.00K | 28.00K | 0.00 |
| Net Income | -4.20M | -13.35M | -6.46M | -5.39M | -10.33M | -6.48M | -7.05M | -2.40M | -4.09M | -6.55M | -7.12M | -5.92M |
| Net Income Ratio | -13.20% | -49.12% | -21.79% | -24.41% | -44.71% | -39.51% | -63.29% | -20.80% | -60.10% | -193.64% | -598.99% | -1,624.27% |
| EPS | -0.13 | -0.43 | -0.21 | -0.24 | -0.50 | -0.39 | -0.48 | -0.17 | -0.28 | -0.46 | -0.55 | -0.49 |
| EPS Diluted | -0.13 | -0.43 | -0.21 | -0.24 | -0.50 | -0.39 | -0.48 | -0.17 | -0.28 | -0.46 | -0.55 | -0.49 |
| Weighted Avg Shares Out | 33.16M | 30.77M | 31.15M | 22.44M | 20.51M | 16.64M | 14.77M | 14.17M | 14.46M | 14.16M | 12.87M | 12.17M |
| Weighted Avg Shares Out (Dil) | 33.16M | 30.77M | 31.15M | 22.44M | 20.51M | 16.64M | 14.77M | 14.51M | 14.46M | 14.26M | 12.87M | 12.17M |
Louisiana Insurer Expands Deep TMS™ Access for 1.9 Million Covered Lives
BURLINGTON, Mass. and JERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Blue Cross Blue Shield of...
BrainsWay: Positive Cash Flow And Continued Growth
BrainsWay reported solid results in Q3 2023 and is now on the verge of sustainable profitability. BrainsWay's focus on larger organizations appears to be supporting growth and improving sales efficiency. While BrainsWay's share price has increased significantly from its lows,...
Brainsway Ltd (BWAY) Q3 2023 Earnings Call Transcript
Brainsway Ltd (NASDAQ:BWAY ) Q3 2023 Earnings Conference Call November 15, 2023 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Hadar Levy - Chief Executive Officer Ido Marom - Chief Financial Officer Conference Call Participants Jayson...
BrainsWay Reports Third Quarter 2023 Financial Results and Operational Highlights
Generated Robust 61% Year-over-Year Revenue Growth in Q3 2023 Nearing Breakeven Operating Income, Achieved Positive Adjusted EBITDA, with Cash Flow from Operations Exceeding $1 Million Conference Call to be Held Today at 8:30 AM EST BURLINGTON, Mass. and JERUSALEM, Nov....
BrainsWay Announces Publication of Study Data on Accelerated Deep Transcranial Magnetic Stimulation (Deep TMS™) for Depression
Peer-reviewed Results Suggest Accelerated Deep TMS Outcomes Comparable to Standard Treatment Protocols Peer-reviewed Results Suggest Accelerated Deep TMS Outcomes Comparable to Standard Treatment Protocols
BrainsWay Broadens Access to Deep TMS™ for U.S. Military Service Members Through Expanded Partnership with Katie's Way Plus
Provider of Mental Health Services with Focus on Military Community Orders 10 New Deep TMS™ Systems Provider of Mental Health Services with Focus on Military Community Orders 10 New Deep TMS™ Systems
Are Medical Stocks Lagging Brainsway (BWAY) This Year?
Here is how Brainsway Ltd. Sponsored ADR (BWAY) and Align Technology (ALGN) have performed compared to their sector so far this year.
BrainsWay Forges Strategic Partnership with Treatment Provider in Northeast U.S.
BURLINGTON, Mass. and JERUSALEM, Sept.
BrainsWay (BWAY) Expands Foothold in Taiwan With Deep TMS
The collaboration between BrainsWay (BWAY) and Unison Healthcare Group signifies a coordinated effort to enhance access and awareness of Deep TMS in Taiwan.
BrainsWay Further Expands Access to Deep TMS™ in Asia Pacific Region
Multisystem Purchases by Unison Healthcare Group Increase Availability of Deep TMS™ in Taiwan Multisystem Purchases by Unison Healthcare Group Increase Availability of Deep TMS™ in Taiwan
Source: https://incomestatements.info
Category: Stock Reports